Back to News
Market Impact: 0.45
Definium Reports Second Phase III Success in Anxiety Disorder Program
Source: zacks.com
Healthcare & BiotechCorporate Guidance & Outlook
DFTX reported a second successful Phase III trial in generalized anxiety disorder, with DT120 ODT delivering statistically significant improvements in anxiety symptoms. The result supports planned FDA discussions and a targeted 2027 regulatory filing, materially advancing the drug candidate toward potential commercialization.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
DFTX0.82
More News
- H.C. Wainwright reiterates Definium stock rating on positive trial data
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- Karin Rådström is steering Daimler Truck in a new direction as the world’s biggest truckmaker faces a growing challenge from China
- Is Amazon Stock a Buy After Its Best Quarter in Years?
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- Alternative Data Due Diligence for Institutional Investors